BIOMARIN PHARMACEUTICAL INC's ticker is BMRN and the CUSIP is 09061G101. A total of 509 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is 0.55 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Farther Finance Advisors, LLC | 36 | $3,185 | 0.00% |
| COMMONWEALTH EQUITY SERVICES, LLC | 7,413 | $656 | 0.00% |
| Sanctuary Wealth Management, L.L.C. | 9 | $796 | 0.00% |
| Financial Management Professionals, Inc. | 35 | $3 | 0.00% |
| Creative Planning | 8,566 | $757,920 | 0.00% |
| Walleye Capital LLC | 5,001 | $442,488 | 0.00% |
| Cresset Asset Management, LLC | 3,608 | $319,236 | 0.00% |
| First Horizon Advisors, Inc. | 432 | $38,222 | 0.00% |
| Lindbrook Capital, LLC | 107 | $9,467 | 0.00% |
| Smithfield Trust Co | 205 | $18 | 0.00% |
| BESSEMER GROUP INC | 5,322 | $471 | 0.00% |
| MACROVIEW INVESTMENT MANAGEMENT LLC | 12 | $1,062 | 0.00% |
| ACADIAN ASSET MANAGEMENT LLC | 3,682 | $325 | 0.00% |
| Hartford Financial Management Inc. | 28 | $2,478 | 0.00% |
| TRUIST FINANCIAL CORP | 5,614 | $496,727 | 0.00% |
| WOLVERINE TRADING, LLC | 7,700 | $681,296 | 0.00% |
| Pacific Center for Financial Services | 30 | $2,655 | 0.00% |
| QUADRANT CAPITAL GROUP LLC | 132 | $11,680 | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 24,300 | $2,150,064 | 0.00% |
| BROWN BROTHERS HARRIMAN & CO | 866 | $76,624 | 0.00% |
About BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative therapies for patients with rare genetic diseases. The company's mission is to provide life-changing treatments that address unmet medical needs and improve the lives of patients and their families.
BioMarin's portfolio includes several approved products, such as Kuvan, Naglazyme, and Vimizim, which are used to treat phenylketonuria, mucopolysaccharidosis VI, and mucopolysaccharidosis IVA, respectively. The company is also developing several other therapies for rare diseases, including gene therapies, enzyme replacement therapies, and small molecule drugs.
BioMarin has a strong pipeline of products in development, with several candidates in late-stage clinical trials. The company's most advanced product candidate is valoctocogene roxaparvovec, a gene therapy for hemophilia A, which is currently under review by the FDA. If approved, valoctocogene roxaparvovec could be a game-changer for patients with hemophilia A, as it has the potential to provide a long-lasting cure for the disease.
BioMarin has a talented team of scientists, researchers, and executives who are dedicated to advancing the company's mission. The company's CEO, Jean-Jacques Bienaime, has been with BioMarin since 2005 and has led the company through several successful product launches and clinical trials.
In conclusion, BioMarin Pharmaceutical Inc. is a leading biotechnology company that is focused on developing innovative therapies for patients with rare genetic diseases. With a strong portfolio of approved products and a promising pipeline of candidates in development, BioMarin is well-positioned to continue making a significant impact in the field of rare disease therapeutics.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIOMARIN PHARMACEUTICAL INC's shareholders in Q3 2023. To view BIOMARIN PHARMACEUTICAL INC's shareholder history, click here.